Published in J Thromb Haemost on October 01, 2010
Recurrent venous thromboembolism: what is the risk and how to prevent it. Scientifica (Cairo) (2012) 0.82
Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach. Curr Treat Options Cardiovasc Med (2013) 0.79
Managing pulmonary embolism using prognostic models: future concepts for primary care. CMAJ (2011) 0.75
Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis. BMJ Open (2014) 0.75
Stopping anticoagulation in a woman with unprovoked venous thromboembolism. CMAJ (2017) 0.75
Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. BMJ Open (2017) 0.75
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med (2001) 3.07
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med (1996) 2.51
Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost (2005) 2.13
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study. J Thromb Haemost (2013) 2.05
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost (2012) 2.04
Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med (1998) 2.03
Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study. EMSALT Study Group. Lancet (2000) 1.95
Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med (1998) 1.90
Recommendations on biosimilar low-molecular-weight heparins. J Thromb Haemost (2009) 1.68
Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia (2010) 1.59
Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. Eur J Intern Med (2010) 1.47
Can evidence harm? Certainly not hemophilia treatment and community. J Thromb Haemost (2006) 1.45
Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev (2006) 1.44
Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost (2004) 1.44
Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation. Br J Haematol (1996) 1.39
Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). Thromb Haemost (1997) 1.27
The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters. Haemophilia (2013) 1.24
Activated protein C resistance in deep-vein thrombosis. Lancet (1994) 1.22
Concentrate-related inhibitor risk: is a difference always real? J Thromb Haemost (2011) 1.22
Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost (2012) 1.11
Intracranial haemorrhage in patients on antithrombotics: clinical presentation and determinants of outcome in a prospective multicentric study in Italian emergency departments. Cerebrovasc Dis (2006) 1.08
Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost (2010) 1.06
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost (2011) 1.06
Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). Haematologica (2001) 1.06
Monilethrix treated with minoxidil. Int J Immunopathol Pharmacol (2011) 1.06
Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol (1999) 1.05
High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost (2008) 1.04
Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. Thromb Haemost (2001) 1.02
The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transpl Surg (1995) 1.01
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. J Thromb Haemost (2012) 1.01
An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. J Thromb Haemost (2008) 1.00
Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. J Thromb Haemost (2012) 0.99
Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. Int J Immunopathol Pharmacol (2013) 0.99
Miconazole oral gel potentiates warfarin anticoagulant activity. Thromb Haemost (2000) 0.97
Value of family history in identifying women at risk of venous thromboembolism during oral contraception: observational study. BMJ (2001) 0.96
Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgery. J Orthop Traumatol (2011) 0.93
Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med (2010) 0.92
Hyperhomocyst(e)inemia and a common methylenetetrahydrofolate reductase mutation (Ala223Val MTHFR) in patients with inherited thrombophilic coagulation defects. Arterioscler Thromb Vasc Biol (1997) 0.92
Isolated distal deep vein thrombosis: efficacy and safety of a protocol of treatment. Treatment of Isolated Calf Thrombosis (TICT) Study. Int Angiol (2009) 0.92
D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis. Thromb Haemost (2011) 0.91
Psychosocial aspects of haemophilia: a systematic review of methodologies and findings. Haemophilia (2011) 0.90
The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol (1997) 0.89
Comparison of disease clusters in two elderly populations hospitalized in 2008 and 2010. Gerontology (2013) 0.89
Mesenteric-portal vein thrombosis in a patient with hyperhomocysteinemia and heterozygous for 20210A prothrombin allele. Thromb Haemost (2000) 0.89
Clinical histories and molecular characterization of two afibrinogenemic patients: insights into clinical management. Haemophilia (2011) 0.89
Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. Eur J Vasc Endovasc Surg (2010) 0.88
D-dimer levels and 15-day outcome in acute pulmonary embolism. Findings from the RIETE Registry. J Thromb Haemost (2009) 0.86
Hereditary thrombophilia and fetal loss: a prospective follow-up study. J Thromb Haemost (2004) 0.86
More on: high thrombin generation and the risk of recurrent venous thromboembolism. J Thromb Haemost (2009) 0.86
Comparison of new rapid methods for D-dimer measurement to exclude deep vein thrombosis in symptomatic outpatients. Blood Coagul Fibrinolysis (1997) 0.85
Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics. Haemophilia (2013) 0.84
Haemophilia Experiences, Results and Opportunities (HERO) Study: influence of haemophilia on interpersonal relationships as reported by adults with haemophilia and parents of children with haemophilia. Haemophilia (2014) 0.84
Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thromb Haemost (1992) 0.84
Post discharge clinically overt venous thromboembolism in orthopaedic surgery patients with negative venography--an overview analysis. Thromb Haemost (1996) 0.83
Venous thromboembolism, oral contraceptives and high prothrombin levels. J Thromb Haemost (2003) 0.83
Patterns of tertiary prophylaxis in Canadian adults with severe and moderately severe haemophilia B. Haemophilia (2014) 0.83
Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors. Haemophilia (2011) 0.83
Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. Haemophilia (2014) 0.82
Towards a recommendation for the standardization of the measurement of platelet-dependent thrombin generation. J Thromb Haemost (2011) 0.81
Central nervous system bleeding in patients with rare bleeding disorders. Haemophilia (2011) 0.81
The Wells rule and D-dimer for the diagnosis of isolated distal deep vein thrombosis. J Thromb Haemost (2012) 0.81
Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. Eur Heart J (2002) 0.81
A new rapid bedside assay for D-dimer measurement (Simplify D-dimer) in the diagnostic work-up for deep vein thrombosis. J Thromb Haemost (2003) 0.81
Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression. J Thromb Haemost (2013) 0.81
Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity. Haemophilia (2013) 0.81
Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: a prospective multicenter study. Thromb Res (2000) 0.81
The first ambulatory screening on thromboembolism: a multicentre, cross-sectional, observational study on risk factors for venous thromboembolism. J Thromb Haemost (2005) 0.81
Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin. Int J Lab Hematol (2014) 0.80
First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System. Haemophilia (2014) 0.80
Aprotinin in orthotopic liver transplantation: evidence for a prohemostatic, but not a prothrombotic, effect. Liver Transpl (2001) 0.80
Prothrombin Molise: a "new" congenital dysprothrombinemia, double heterozygosis with an abnormal prothrombin and "true" prothrombin deficiency. Blood (1978) 0.80
In-hospital death according to dementia diagnosis in acutely ill elderly patients: the REPOSI study. Int J Geriatr Psychiatry (2010) 0.80
In-hospital death and adverse clinical events in elderly patients according to disease clustering: the REPOSI study. Rejuvenation Res (2010) 0.80
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation. J Intern Med (2012) 0.80
HemosIL D-dimer HS assay in the diagnosis of deep vein thrombosis and pulmonary embolism. Results of a multicenter management study. J Thromb Haemost (2008) 0.80
Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation. Blood Coagul Fibrinolysis (1999) 0.80
Ascites apheresis, concentration and reinfusion for the treatment of massive or refractory ascites in cirrhosis. J Hepatol (1994) 0.80
Contribution of a new, rapid, quantitative and automated method for D-dimer measurement to exclude deep vein thrombosis in symptomatic outpatients. Blood Coagul Fibrinolysis (1999) 0.79
Prolonged very low calorie diet in highly obese subjects reduces plasma viscosity and red cell aggregation but not fibrinogen. Int J Obes Relat Metab Disord (1994) 0.79
Successful treatment with rFVIIa of spontaneous intracerebral hemorrhage in a patient with mechanical prosthetic heart valves. Clin Lab Haematol (2005) 0.79
Inhibition of lymphoma growth in the spleen and liver of lethally irradiated mice. J Immunol (1978) 0.79
II Italian intersociety consensus statement on antithrombotic prophylaxis in orthopaedics and traumatology: arthroscopy, traumatology, leg immobilization, minor orthopaedic procedures and spine surgery. J Orthop Traumatol (2012) 0.79
Haemophilia Experiences, Results and Opportunities (HERO) study: treatment-related characteristics of the population. Haemophilia (2014) 0.79
Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. Hepatology (2000) 0.79
Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. J Thromb Haemost (2010) 0.79
Thrombotic risk factors and cardiovascular events after endovascular intervention for peripheral arterial disease. Eur J Vasc Endovasc Surg (2011) 0.79
Aromatase inhibitors induce 'male pattern hair loss' in women? Ann Oncol (2013) 0.79
Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction. J Lab Clin Med (1995) 0.78
Systemically circulating oxidative species in human deep venous thrombosis. Eur J Emerg Med (1998) 0.78
Efficacy of Iralfaris shampoo in the treatment of scalp psoriasis: a videodermoscopy evaluation prospective study in 70 patients. G Ital Dermatol Venereol (2012) 0.78
Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. J Thromb Haemost (2015) 0.78
Influenza vaccination in patients on long-term anticoagulant therapy. Vaccine (2006) 0.78
Factor VIII: C levels during oral anticoagulation and after its withdrawal. Thromb Haemost (1995) 0.78
The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study. J Thromb Haemost (2009) 0.78